Last reviewed · How we verify
NCT06073938
Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement
trial testing NHWD-870 in Advanced Solid Tumors or Lymphomas in 30 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | Hunan Province Tumor Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 20 September 2022 |
| Primary completion | 31 December 2024 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- NHWD-870 — full drug profile →
Conditions studied
- Advanced Solid Tumors or Lymphomas — all drugs for Advanced Solid Tumors or Lymphomas →
Sponsor
Hunan Province Tumor Hospital
Who can join
Adults 18 to 75, any sex, with Advanced Solid Tumors or Lymphomas. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The NHWD-870 Phase I clinical trial evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics in patients with advanced tumors. The objectives of this retrospective study were to preliminarily evaluate the anti-tumor efficacy of NHWD-870 HCl in patients with advanced solid tumors or lymphomas and to preliminarily evaluate biomarkers associated with the efficacy of NHWD-870 HCl in the treatment of patients with advanced solid tumors or lymphomas, to provide a basis for identifying the enriched population for the late-stage trial.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Complete Response to BET Inhibitor in Primary Pulmonary NUT Carcinoma With Single-Cell Sequencing-Based Analysis: A Case Report.
Ye Z, Li X, Zhang M, Xie F, et al · · 2025 · cited 1× · PMID 40926997 · DOI 10.1016/j.jtocrr.2025.100885 -
Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies.
Giercuszkiewicz-Haśnik K, Morak-Młodawska B, Jeleń M. · · 2026 · PMID 41976235 · DOI 10.3390/molecules31071195 -
A nationwide survey of awareness and understanding of NUT carcinoma among clinicians in China.
Ye Z, Yang D, Liu W, Li X, et al · · 2026 · PMID 41772604 · DOI 10.1186/s12913-026-14236-4
Verify or expand the search:
- PubMed search for NCT06073938
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Hunan Province Tumor Hospital trials
Trials by the same sponsor.
- NCT06706219 — Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unres · Phase 2 · not yet recruiting
- NCT07001995 — Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression · Phase 2 · not yet recruiting
- NCT07477808 — Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer · Phase 3 · not yet recruiting
- NCT07251582 — Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06073938 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hunan Province Tumor Hospital
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06073938.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing